DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTFree Report) in a research report released on Sunday morning. The firm issued a hold rating on the stock.

A number of other brokerages have also weighed in on DBVT. HC Wainwright boosted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th.

Get Our Latest Stock Report on DBVT

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $4.15 on Friday. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.49. The stock’s 50-day moving average is $3.75 and its 200 day moving average is $3.87. The company has a market cap of $85.38 million, a PE ratio of -0.92 and a beta of 0.64.

DBV Technologies (NASDAQ:DBVTGet Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $1.10. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.17 million. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Analysts expect that DBV Technologies will post -7.05 EPS for the current fiscal year.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.

Featured Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.